Distinct KIR3DL1 subtype variants, combined with the specific HLA-B ligand subtype, could lead to various levels of inhibition on NK cells and relapse protection in AML patients after HSCT (18). The gene discussed is HLA-B; the disease is acute myeloid leukemia.